Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience

Triple-negative breast carcinoma (TNBC) patients do not benefit from hormone- or human epidermal growth factor receptor 2- (HER2-) targeted therapies. Accurate testing is pivotal for these patients.

https://cancerci.biomedcentral.com/articles/10.1186/s12935-019-0987-7

Source: Cancer Cell International - October 11, 2019 Category: Cancer & Oncology Authors: Jose De Jesus and Marilin Rosa Tags: Primary research Source Type: research